Refracture following vertebral fragility fracture when bone fragility is not recognized: summarizing findings from comparator arms of randomized clinical trials.
Refracture
Subsequent fractures
Systematic review
Vertebral fragility fracture
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
received:
19
06
2023
accepted:
10
10
2023
medline:
3
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
aheadofprint
Résumé
Since vertebral fragility fractures (VFFs) might increase the risk of subsequent fractures, we evaluated the incidence rate and the refracture risk of subsequent vertebral and non-vertebral fragility fractures (nVFFs) in untreated patients with a previous VFF. We systematically searched PubMed, Embase, and Cochrane Library up to February 2022 for randomized clinical trials (RCTs) that analyzed the occurrence of subsequent fractures in untreated patients with prior VFFs. Two authors independently extracted data and appraised the risk of bias in the selected studies. Primary outcomes were subsequent VFFs, while secondary outcomes were further nVFFs. The outcome of refracture within ≥ 2 years after the index fracture was measured as (i) rate, expressed per 100 person-years (PYs), and (ii) risk, expressed in percentage. Forty RCTs met our inclusion criteria, ranging from medium to high quality. Among untreated patients with prior VFFs, the rate of subsequent VFFs and nVFFs was 12 [95% confidence interval (CI) 9-16] and 6 (95% CI 5-8%) per 100 PYs, respectively. The higher the number of previous VFFs, the higher the incidence. Moreover, the risk of VFFs and nVFFs increased within 2 (16.6% and 8%) and 4 years (35.1% and 17.4%) based on the index VFF. The highest risk of subsequent VFFs or nVFFs was already detected within 2 years following the initial VFF. Thus, prompt interventions should be designed to improve the detection and treatment of VFFs, aiming to reduce the risk of future FFs and properly implement secondary preventive measures.
Identifiants
pubmed: 37921990
doi: 10.1007/s40618-023-02222-0
pii: 10.1007/s40618-023-02222-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Dang DY, Zetumer S, Zhang AL (2019) Recurrent fragility fractures: a cross-sectional analysis. J Am Acad Orthop Surg 27:e85-91
pubmed: 30169444
doi: 10.5435/JAAOS-D-17-00103
Capdevila-Reniu A, Navarro-López M, López-Soto A (2019) Osteoporotic vertebral fractures: a diagnostic challenge in the 21st century. Rev Clin Esp S0014–2565(19):30240–30241
Wong RMY, Wong PY, Liu C, Wong HW, Chung YL, Chow SKH et al (2022) The imminent risk of a fracture-existing worldwide data: a systematic review and meta-analysis. Osteoporos Int 33:2453–2466
pubmed: 35776148
doi: 10.1007/s00198-022-06473-0
Liu J, Curtis EM, Cooper C, Harvey NC (2019) State of the art in osteoporosis risk assessment and treatment. J Endocrinol Invest 42:1149–1164
pubmed: 30980341
pmcid: 6751157
doi: 10.1007/s40618-019-01041-6
Adami G, Biffi A, Porcu G, Ronco R, Alvaro R, Bogini R et al (2023) A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA FRA-HS. J Endocrinol Invest. https://doi.org/10.1007/s40618-023-02082-8
doi: 10.1007/s40618-023-02082-8
pubmed: 37031450
pmcid: 10558377
Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E et al (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780
pubmed: 28028554
doi: 10.1007/s00198-016-3868-0
Luo C, Qin SX, Wang QY, Li YF, Qu XL, Yue C et al (2023) Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk. J Endocrinol Invest 46:367–379
pubmed: 36044169
doi: 10.1007/s40618-022-01910-7
Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A et al (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30:79–92
pubmed: 30456571
doi: 10.1007/s00198-018-4732-1
Barton DW, Behrend CJ, Carmouche JJ (2019) Rates of osteoporosis screening and treatment following vertebral fracture. Spine J 19:411–417
pubmed: 30142455
doi: 10.1016/j.spinee.2018.08.004
Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936
pubmed: 12057569
doi: 10.1016/S0140-6736(02)08761-5
McDonald CL, Alsoof D, Daniels AH (2013) Vertebral compression fractures. R I Med J 2022(105):40–45
Robinson WA, Carlson BC, Poppendeck H, Wanderman NR, Bunta AD, Murphy S et al (2020) Osteoporosis-related vertebral fragility fractures: a review and analysis of the American Orthopaedic Association’s own the bone database. Spine 45:E430–E438
pubmed: 31770343
doi: 10.1097/BRS.0000000000003324
Bottai V, Giannotti S, Raffaetà G, Mazzantini M, Casella F, De Paola G et al (2016) Underdiagnosis of osteoporotic vertebral fractures in patients with fragility fractures: retrospective analysis of over 300 patients. Clin Cases Miner Bone Metab 13:119–122
pubmed: 27920807
pmcid: 5119708
Howlett DC, Drinkwater KJ, Griffin J, Javaid K (2020) Improving outcomes for patients with osteoporotic vertebral fragility fractures: the role of the radiologist. Clin Radiol 75:811–812
pubmed: 32883515
doi: 10.1016/j.crad.2020.07.020
Alsoof D, Anderson G, McDonald CL, Basques B, Kuris E, Daniels AH (2022) Diagnosis and management of vertebral compression fracture. Am J Med 135:815–821
pubmed: 35307360
doi: 10.1016/j.amjmed.2022.02.035
Zileli M, Fornari M, Costa F, Anania CD, Parthiban J, Sharif S (2022) Epidemiology, natural course, and preventive measures of osteoporotic vertebral fractures: WFNS Spine Committee Recommendations. J Neurosurg Sci 66:282–290
pubmed: 35301844
Zeytinoglu M, Jain RK, Vokes TJ (2017) Vertebral fracture assessment: enhancing the diagnosis, prevention, and treatment of osteoporosis. Bone 104:54–65
pubmed: 28285014
doi: 10.1016/j.bone.2017.03.004
Borges JLC, Maia JL, Silva RF, Lewiecki EM (2015) Diagnosing vertebral fractures: missed opportunities. Rev Bras Reumatol 55:464–467
pubmed: 25772659
doi: 10.1016/j.rbr.2014.12.008
Lems WF, Paccou J, Zhang J, Fuggle NR, Chandran M, Harvey NC et al (2021) Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int 32:399–411
pubmed: 33475820
pmcid: 7929949
doi: 10.1007/s00198-020-05804-3
Reid IR, Bolland MJ (2020) Calcium and/or vitamin D supplementation for the prevention of fragility fractures: who needs it? Nutrients 12:1011
pubmed: 32272593
pmcid: 7231370
doi: 10.3390/nu12041011
Page MJ, Moher D (2017) Evaluations of the uptake and impact of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and extensions: a scoping review. Syst Rev 6:263
pubmed: 29258593
pmcid: 5738221
doi: 10.1186/s13643-017-0663-8
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
pubmed: 22008217
pmcid: 3196245
doi: 10.1136/bmj.d5928
Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129. https://doi.org/10.2307/3001666
doi: 10.2307/3001666
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
pubmed: 12958120
pmcid: 192859
doi: 10.1136/bmj.327.7414.557
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
pubmed: 3802833
doi: 10.1016/0197-2456(86)90046-2
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
pubmed: 9310563
pmcid: 2127453
doi: 10.1136/bmj.315.7109.629
Lippuner K (2003) Medical treatment of vertebral osteoporosis. Eur Spine J 12(Suppl 2):S132-141
pubmed: 13680313
pmcid: 3591820
doi: 10.1007/s00586-003-0608-x
Boonen S, Laan RF, Barton IP, Watts NB (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291–1298
pubmed: 15986101
doi: 10.1007/s00198-005-1945-x
Francis RM, Anderson FH, Torgerson DJ (1995) A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 34:1167–1171
pubmed: 8608360
doi: 10.1093/rheumatology/34.12.1167
Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17:313–316
pubmed: 16217588
doi: 10.1007/s00198-005-2030-1
Kobayashi T, Kaneko M, Narukawa M (2020) Influence of prevalent vertebral fracture on the correlation between change in lumbar spine bone mineral density and risk of new vertebral fracture: a meta-analysis of randomized clinical trials. Clin Drug Investig 40:15–23
pubmed: 31630338
doi: 10.1007/s40261-019-00868-4
Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA et al (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the fracture intervention trial. Arch Intern Med 157:2617–2624
pubmed: 9531231
doi: 10.1001/archinte.1997.00440430099012
Sontag A, Wan X, Krege JH (2010) Benefits and risks of raloxifene by vertebral fracture status. Curr Med Res Opin 26:71–76
pubmed: 19908937
doi: 10.1185/03007990903427082
Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P et al (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20:1663–1673
pubmed: 19153678
pmcid: 2744775
doi: 10.1007/s00198-008-0825-6
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
pubmed: 11346808
doi: 10.1056/NEJM200105103441904
Prevrhal S, Krege JH, Chen P, Genant H, Black DM (2009) Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 25:921–928
pubmed: 19250060
doi: 10.1185/03007990902790993
Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M et al (2014) Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the teriparatide once-weekly efficacy research (TOWER) trial. J Bone Miner Metab 32:441–446
pubmed: 24213216
doi: 10.1007/s00774-013-0505-2
Wustrack R, Seeman E, Bucci-Rechtweg C, Burch S, Palermo L, Black DM (2012) Predictors of new and severe vertebral fractures: results from the HORIZON pivotal fracture trial. Osteoporos Int 23:53–58
pubmed: 21691843
doi: 10.1007/s00198-011-1664-4
Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P et al (1998) Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 8:4–12
pubmed: 9692071
doi: 10.1007/s001980050041
Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR et al (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339
pubmed: 17339618
doi: 10.7326/0003-4819-146-5-200703060-00005
McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728–736
pubmed: 15068495
doi: 10.1359/jbmr.040116
Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K (1997) The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporos Int 7:52–58
pubmed: 9102064
doi: 10.1007/BF01623461
Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PHLM, Hamdy NAT, Landman JO et al (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17:1057–1064
pubmed: 12054161
doi: 10.1359/jbmr.2002.17.6.1057
Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K et al (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437
pubmed: 19101754
doi: 10.1007/s00198-008-0816-7
Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y et al (2013) Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the Minodronate trial. J Bone Miner Metab 31:544–550
pubmed: 23529800
doi: 10.1007/s00774-013-0439-8
Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7:488–495
pubmed: 9425508
doi: 10.1007/PL00004152
Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T (2014) Once-weekly injection of low-dose teriparatide (28.2 μg) reduced the risk of vertebral fracture in patients with primary osteoporosis. Calcif Tissue Int 94:170–175
pubmed: 23963633
doi: 10.1007/s00223-013-9777-8
Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallack RW, Dhaliwal SS et al (2002) A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. Osteoporos Int 13:158–170
pubmed: 11908491
doi: 10.1007/s001980200008
Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104:219–226
pubmed: 9552083
doi: 10.1016/S0002-9343(98)00029-1
Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249
pubmed: 15231010
doi: 10.1359/JBMR.040325
Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37:651–654
pubmed: 16126016
doi: 10.1016/j.bone.2005.05.004
Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96:1727–1736
pubmed: 21411557
doi: 10.1210/jc.2010-2784
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Interv Trial Res Group Lancet 348:1535–1541
Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532
pubmed: 14555255
doi: 10.1016/S8756-3282(03)00241-2
Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468
pubmed: 14749454
doi: 10.1056/NEJMoa022436
Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study PROOF study group. Am J Med 109:267–276
pubmed: 10996576
doi: 10.1016/S0002-9343(00)00490-3
Recker RR, Hinders S, Davies KM, Heaney RP, Stegman MR, Lappe JM et al (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11:1961–1966
pubmed: 8970899
doi: 10.1002/jbmr.5650111218
Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84:401–408
pubmed: 3279769
doi: 10.1016/0002-9343(88)90259-8
Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113:649–655
pubmed: 2221645
doi: 10.7326/0003-4819-113-9-649
Ott SM, Chesnut CH (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 110:267–274
pubmed: 2913914
doi: 10.7326/0003-4819-110-4-267
Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123:401–408
pubmed: 7639438
doi: 10.7326/0003-4819-123-6-199509150-00001
Ringe JD, Kipshoven C, Cöster A, Umbach R (1999) Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int 9:171–178
pubmed: 10367046
doi: 10.1007/s001980050132
Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362
pubmed: 1729617
doi: 10.1056/NEJM199202063260601
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 344:333–340
pubmed: 11172164
doi: 10.1056/NEJM200102013440503
Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC et al (1991) A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1:155–161
pubmed: 1790403
doi: 10.1007/BF01625446
Lufkin EG, Wahner HW, O’Fallon WM, Hodgson SF, Kotowicz MA, Lane AW et al (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1–9
pubmed: 1534476
doi: 10.7326/0003-4819-117-1-1
Riggs BL, Hodgson SF, O’Fallon WM, Chao EY, Wahner HW, Muhs JM et al (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–809
pubmed: 2407957
doi: 10.1056/NEJM199003223221203
Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–1271
pubmed: 2109197
doi: 10.1056/NEJM199005033221803
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79
pubmed: 2113611
doi: 10.1056/NEJM199007123230201
Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK et al (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747–1754
pubmed: 9797484
doi: 10.1359/jbmr.1998.13.11.1747
Recker R, Stakkestad JA, Chesnut CH, Christiansen C, Skag A, Hoiseth A et al (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899
pubmed: 15121021
doi: 10.1016/j.bone.2004.01.008
Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P et al (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557–567
pubmed: 8259772
doi: 10.1016/0002-9343(93)90350-X
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43
pubmed: 28425085
pmcid: 5397452
doi: 10.1007/s11657-017-0324-5
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739
pubmed: 10780864
doi: 10.1359/jbmr.2000.15.4.721
Adams J, Clark EM, Clunie G (2017) Clinical guidance for the effective identification of vertebral fractures. National Osteoporosis Society, Bath
Adams JE, Lenchik L, Roux C, Genant HK. Radiological assessment of vertebral fracture. International osteoporosis foundation vertebral fracture initiative resource document part II 2010.